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Abstract Binding sites for different transcription factors have 
been identified in the regulatory region of the human uPA gene. 
We investigated the role of NF-r,B and AP-1 families of 
transcription factors in the induction of uPA mRNA by TNF-a 
and PMA in the A549 cell line constitutively expressing uPA 
mRNA and protein. Using the protein synthesis inhibitor 
cydoheximide and the antioxidant PDTC, that have an opposite 
effect on NF-r,B and AP-1 activation, we showed that uPA 
mRNA induction by TNF-a and PMA in the A549 cell line is 
mainly due to NF-r,B activation. 
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1. Introduction 
Urokinase-type lasminogen activator (uPA) is involved in 
regulating biochemical phenomena leading to migration and 
invasiveness of normal and cancer cells. Although not essen- 
tial for embryonic and fetal development [1], an important 
role of uPA seems established in promoting fibrinolysis, chem- 
otaxis, angiogenesis and invasiveness in normal as well as 
pathologic processes like inflammation and cancer [2]. uPA 
expression can be induced or enhanced in culture and in 
vivo by physiological stimuli (cytokines, growth factors), 
phorbol esters (PMA) and during neoplastic transformation 
[3]. 
The upstream regulatory region of the human uPA gene has 
been studied in some detail and two distinct regions able to 
mediate responsiveness to phorbol esters have been identified: 
an upstream enhancer located between -2100/-1870 and a 
~cB-like sequence element at -1592/-1582 [4-7]. The enhancer 
region contains everal binding sites for known transcription 
factors: an octameric AP-1 binding site combined with a 
PEA3 site is present at the 5' of the enhancer region while a 
consensus heptameric AP-1 site is located at the 3' end. Both 
these sites are required for basal and induced enhancer activ- 
ity [6,8]. The second phorbol esters responsive region, located 
at -1592, binds members of the NF-~:B/Rel family of tran- 
scription factors [9], in particular the two heterodimers 
NF~cB1/RelA and c-Rel/RelA [7,10,11]. 
The A549 is a human pulmonary epithelial cell line derived 
from an alveolar cell carcinoma that constitutively expresses 
uPA mRNA [12], in which both uPA mRNA and protein 
levels can be stimulated by TNF-a [13]. In order to determine 
the individual roles of NF-•B and AP-1 transcription factors 
in regulating uPA gene expression, we have analyzed uPA 
mRNA expression in the A549 cell line following treatment 
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with TNF-a or a phorbol ester, the 12-O-tetradecanoyl-phor- 
bol-13-acetate (PMA). Our data indicate that the Rel family 
factors play an important role in TNF-a as well as PMA 
induction of uPA gene transcription. 
2. Materials and methods 
2.1. Cell culture 
The human pulmonary epithelial cell line A549 [12] was maintained 
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal calf serum (FCS). Stimulations were carried out with re- 
combinant human TNF-a (specific activity: 3.2 x 107 U/mg) at a final 
concentration f 100 U/ml; PMA at 100 ng/ml and cycloheximide at 
10 gg/ml. 
2.2. Plasmid probes and Northern blot assay 
The following fragments were used as probes in Northern blotting 
analyses: the 1.5 kb PstI fragment of human uPA cDNA [14]. Human 
cDNAs for NF-~cB1 (p50), RelA (p65) and bcB-a have been pre- 
viously described [10]. Murine 1.3 kb c-Fos cDNA was from the 
plasmid T7~c-Fos [15]; the human 350 bp c-Jun cDNA probe was 
from the plasmid pUN21c-Jun [16]. cDNA probes were labeled with 
[a-a2P]dCTP by the Random Primed DNA labeling Kit (Boehringer). 
Total RNA was extracted from ceils by the guanidinium isothiocya- 
nate method [17]. RNAs (20 gg) were loaded on 1% formaldehyde- 
containing agarose gels and transferred toa nitrocellulose membrane 
(BioRad). The intensity of RNA bands in the autoradiographs was 
quantitated by a video densitometer (Molecular Dynamics). 
2.3. Nuclear extract and electrophoretic mobility shift assay 
Nuclear and cytoplasmic extracts from cultured cells were prepared 
according to published methods [7,18]. DNA binding ability of 10 gg 
of nuclear extracts was analized by the electrophoretic mobility shift 
assay (EMSA) [7]. The oligonucleotides used for EMSA were labeled 
with [?-32P]ATP and were: 
~B : 5'-GCTGCCTGCTGGGGAAAGTAC-3', 
corresponding to nucleotides -1592/-1571 ofthe human uPA gene; 
AP-I:5'-GAGCAACATGAATCATGACGG-3', 
corresponding to nucleotides -1893/1872 of the human uPA gene. 
3. Results 
3.1. Induction of  uPA mRNA by PMA and TNF-a 
To determine the effect of TNF-ct and PMA on the expres- 
sion of the endogenous uPA gene in A549 cells, total RNA 
from control, TNF-a- or PMA-treated cells was analyzed by 
Northern blotting and hybridized with the uPA cDNA probe. 
The same filters were sequentially hybridized to a GAPDH 
probe, for loading control. Unstimulated cells expressed e- 
tectable levels of the 2.5 kb uPA mRNA (Fig. 1A, lane C). 
Treatment of the cells with TNF-c~ (100 U/ml) resulted in 
increase of uPA mRNA which peaked at 3 h (5-fold compared 
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to untreated cells), and declined thereafter. Treatment of the 
cells with PMA resulted in a strong increase of uPA mRNA 
(10-fold at 3 h) (Fig. 1C). Quantitation of the data by densi- 
tometric analysis of the filters is shown in Fig. 1B,D. 
3.2. Effects of  PMA and TNF-~ on expression of  the 
ReIINFr, B and Jun/Fos family members 
We next analysed the effect of TNF-tx and PMA on the 
expression of genes of the Rel family and c-Jun and c-Fos 
families that may be involved in basal and inducible expres- 
sion of the uPA gene [7,8]. As shown in Fig. 2, the 2.6 kb 
mRNA of RelA, was induced by TNF-a (Fig. 2A) and to a 
lesser extent by PMA (Fig. 2B). The low levels of the two c- 
Rel mRNA (3.5 kb and > 10 kb) were essentially unaffected 
by PMA or TNF-c~ (data not shown). 
On the other hand both NFKB1 and I~B-ct mRNAs, known 
to be regulated through NF-~B sites [19,20], were strongly 
induced by treatment with TNF-ct and PMA; the 3.8 kb 
mRNA for NFKB1 reached a maximum 15-fold increase 
with PMA and 6.5-fold with TNF-a (Fig. 2A,B). The 
mRNA levels of IKB-ct (Fig. 2A) upon TNF-tx stimulation 
dramatically increased at 1 h, reached a maximum at 3 h, 
and decreased at 5 h. PMA was less effective than TNF-t~ 
to induce IKB-tx mRNA (Fig. 2B). 
In addition to the ~cB, the AP-1 site located in the uPA 
enhancer region is also a candidate in mediating up-regulation 
of uPA mRNA by TNF-et and PMA [8]. We therefore inves- 
tigated the effects of TNF-ct and PMA on the expression of 
the AP-1 subunits c-Jun and c-Fos. The filters were sequen- 
tially hybridized to eDNA probes for c-Jun and c-Fos, which 
in HepG2 cells bind as an heterodimeric complex to the hep- 
tameric AP-1 binding site at the 3' of the uPA enhancer e- 
gion [8]. Results showed that c-Jun mRNA was undetectable 
in untreated cells (Fig. 2A); TNF-ct and PMA treatment had 
little effect on its level (Fig. 2A,B). c-Fos mRNA was also 
undetectable in untreated cells (Fig. 2A), and PMA and 
TNF-ct had no effect on its expression (Fig. 2A,B). 
From the data of Figs. 1 and 2 we conclude that uPA 
induction by TNF-c~ and PMA better correlates with activa- 
tion of NF-~cB family members. 
3.3. uPA mRNA induction by TNF-oL and PMA does not 
require de novo protein synthesis 
To investigate whether induction of uPA mRNA by TNF-ct 
or PMA was dependent on de novo protein synthesis, we 
employed the protein synthesis inhibitor cycloheximide 
(CHX). Treatment of the cells with CHX (10 ~tg/ml) for 1, 
3 and 5 h resulted in an increase of uPA mRNA (Fig. 1A); 
co-treatment of cells with CHX and TNF-ct or CHX and 
PMA showed a further 10- and 30-fold increase, respectively, 
of the uPA mRNA levels (Fig. IA,C). 
CHX alone induced or, together with TNF-tx or PMA, 
superinduced RelA, NF-KB1 and I~cB-ct mRNAs (Fig. 
2A,B); CHX has been reported to directly activate NF-~B 
[21]• CHX treatment also induced c-Jun mRNA, the levels 
of which increased in a time-dependent manner; TNF-ct in 
combination with CHX determined an early and transitory 
stimulation of c-jun mRNA levels (Fig. 2A). PMA/CHX 
treatments revealed a 2.2 kb c-Fos mRNA at 5 and 8 h 
(Fig. 2B) but no c-Fos mRNA band was observed with 
CHX or PMA alone. 
From these data we concluded that uPA mRNA induction 
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Fig. 1. uPA mRNA induction in A549 cells by TNF-o~ and PMA. 
Northern blot analysis of A549 cell mRNAs; 20 Ixg of mRNA for 
each sample was loaded on a 1% formaldheyde-agarose gel.A and 
C: Northern blots. B and D: Quantitation of the data in (A) and 
(C) after densitometric s anning of the autoradiographs: mRNA in- 
tensities were calculated relative to the intensities of the GAPDH in- 
ternal mRNA control (A.U., arbitrary units). C = control cells (un- 
treated). CHX = cycloheximide. 
by TNF-ct and PMA does not require de novo protein syn- 
thesis. Hence again the correlation between increase of uPA 
mRNA and RelA/c-Rel mRNA, may only be relevant upon 
long-term stimulations. 
3.4. Effects of TNF-ot and PMA on DNA binding activity of 
NF-r~B and AP-1 
NF-~B activation, resulting in nuclear translocation, does 
not need protein synthesis. To test NF-~cB DNA binding ac- 
tivity, nuclear protein extracts from untreated and treated 
cells were analized by EMSA, using as a probe an oligonu- 
cleotide corresponding to the degenerate KB site present at 
--1592 of the human uPA gene. This sequence has been pre- 
viously shown to bind several members of the Rel gene family 
[7]. The A549 nuclear extract had a very low constitutive 
binding activity (Fig. 3, lane 1). Following stimulation with 
PMA (lane 3) and TNF-ct (lane 5) DNA binding was in- 
duced; TNF-ct was a better inducer of NF-~cB DNA binding 
activity. Interestingly, CHX synergized with PMA (lane 4) 
and with TNF-et (lane 6): this effect may possibly be due 
either to the prevention of I~B-tx synthesis, a protein with a 
very short half-life [20], or to a direct activation of NF-~cB by 
CHX [21]. The specificity of the binding activity was shown 
by the competition with an unlabeled KB oligonucleotide 
(lanes 7 and 8); an AP-1 binding oligonucleotide (lanes 9 
and 10) did not compete• Identical data were obtained using 
a ~B site derived from the HIV enhancer (data not shown) 
[221. 
Next, we examined the effects of PMA and TNF-ac on AP-1 
binding activity. An oligonucleotide corresponding to the con- 
sensus AP-1 binding site at the 3' of the uPA enhancer was 
used as a probe. The results (Fig. 3) showed that the A549 cell 
line had a consistent specific basal AP-1 activity (lane 1), 
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Fig. 2. The mRNAs of NF-r,B and AP-1 subunits are differently 
regulated by TNF-ct and PMA. The same filters of Fig. 1A,C were 
sequentially hybridized with cDNA probes for RelA, NFr, B1, I~:B- 
ct, c-fos and c-jun. C = control cells (untreated). 
which was specifically competed for by the unlabeled AP-1 
(lanes 7 and 8) but not by the loB oligonucleotide (lanes 9 
and 10). The AP-1 binding activity was increased after treat- 
ment with PMA (lane 3) but not with TNF-ct (lane 5). Co- 
treatment of PMA with CHX abolished PMA induction (lane 
4). 
In conclusion, NF-~B was activated by PMA and TNF-ct 
also in the presence of CHX; activation of NF-KB therefore is 
coincident with the lack of cycloeximide sensitivity of the uPA 
mRNA induction by PMA and TNF-c~, On the other hand 
AP-1 responded poorly to PMA and not at all to TNF-tx, and 
CHX abolished the modest PMA induction. 
3.5. Effects o f  PDTC treatment on DNA binding activities and 
uPA mRNA levels 
In order to investigate whether NF-KB DNA binding activ- 
ity was involved in up-regulating uPA mRNA level, we em- 
ployed the antioxidant PDTC (pyrrolidinedithiocarbamate) 
that has been reported to inhibit NF-KB activation while in- 
ducing AP-1 activity [23]. Nuclear extracts were prepared 
from A549 cells treated for 1 h with PDTC (100 and 150 
gtM) prior to the addition of PMA or TNF-ct. As shown in 
Fig. 4, treatment with PDTC alone (lanes 2 and 3) did not 
induce NF-~cB binding activity. On the other hand the PMA- 
induced ~cB binding (lane 4) was abolished by PDTC treat- 
ment (lanes 5 and 6); the same results were obtained with 
TNF-tx/PDTC co-treatments (compare lane 7 to lanes 8 and 
9). Again the different extent of NF-~cB activation by PMA 
and TNF-ct (compare lane 4 to lane 7) is noticeable. When the 
same extracts were incubated with an AP-1 oligonucleotide, 
the opposite result was obtained. AP-1 binding activity was 
induced by PDTC alone (Fig. 4, compare lane 1 with lanes 2 
and 3) and co-treatment of PMA with PDTC (lanes 5 and 6) 
resulted in even greater induction of AP-1 binding activity 
than with PMA alone (lane 4); PDTC did not increase, how- 
ever, the activity of cells treated with TNF-ct (lanes 7 and 8). 
We then analysed uPA mRNA levels in PMA- or TNF-tx- 
treated cells for 3 h, in the presence and absence of PDTC. As 
shown in Fig. 5A PDTC alone weakly induced uPA mRNA 
levels (3-fold, lane 2) possibly through AP-1 activation; PMA/ 
PDTC co-treatment, however, resulted in a decrease of uPA 
mRNA (lane 4) compared to treatments with PMA alone 
(lane 3). Similar results were obtained with TNF-odPDTC 
co-treatments (lanes 5 and 6). Quantitation of the data (Fig. 
5B) showed that the presence of PDTC decreased the level of 
uPA mRNA in PMA- and TNF-c(-treated cells by 60 and 
50%, respectively. We then reprobed the same filter with the 
hcB-~ probe, a gene known to be under NF-KB transcrip- 
tional control [20]. The results showed that also in the case 
of IKB-ct PMA and TNF-ct inductions could be partially 
blocked by PDTC (Fig. 5A, lanes 3-6). 
CXX ,. + - , . 
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Fig. 3. PMA and TNF-~t specifically induce NF-r,B binding to a ~B 
site of the human uPA gene. An oligonucleotide corresponding to
the r,B site at -1590 was used as probe in experiment of electro- 
phoretic mobility shift assay (EMSA) with nuclear extracts derived 
from A549 cells. Untreated cells (lane 1). CHX treatment for 3 h 
(lane 2); PMA treatment was for 3 h (lane 3). Lane 4; co-treatment 
of PMA/CHX for 3 h. TNF-ct treatments (lane 5, 3 h). Co-treat- 
ment of TNF-oJCHX for 3 h (lane 6). DNA binding specificity of 
TNF-tx-treated nuclear extract was assesed with 20- and 60-fold ex- 
cess of unlabeled oligonucleotide (lanes 7 and 8) and with 20- and 
60-fold excess of the unrelated AP-1 oligonucleotide (lanes 9 and 
10). The same nuclear extracts used were used in an EMSA experi- 
ment with a oligonucleotide spanning the canonical AP-1 of the hu- 
man uPA gene as probe. 
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4. Discussion 
The data reported in this paper show that in A549 cells 
induction of uPA mRNA by PMA and TNF-ct requires 
NF-rB, a factor already present in an inactive form in the 
cytoplasm of these cells. Although induction of uPA mRNA 
correlated with that of RelA and NF-~cB1 mRNAs, the lack 
of sensitivity of uPA mRNA induction to the block of protein 
synthesis indicates that inductions of RelA and NF~cB1 
mRNAs were not influential. This may possibly be due to 
the strong induction of I~¢B-c( mRNA observed, a result al- 
ready described by others and in line with NF-~cB regulation 
of the IrB-ct gene [20]. Indeed, despite the induction of bcB-et, 
treatment of A549 cells with PMA and TNF-ct resulted in 
activation of the NF-~cB DNA binding activity, suggesting 
that the increase in factors and inhibitors had a mutually 
exclusive ffect. On the other hand, PMA and TNF-ct had 
no effect on the levels of expression of the two major subunits 
of the AP-1 transcription factor, c-Jun and c-Fos. This result 
parallels the failure to demonstrate a major induction of DNA 
binding activity to the AP-1 sequence (Fig. 3) in particular by 
TNF-cc Since the antioxidant PDTC induces AP-1 binding, 
while inhibiting NF-~B activity [23], we have used this com- 
pound to discriminate between the two sets of transcription 
factors (Figs. 4 and 5). Both in the case of PMA and TNF-(~, 
uPA mRNA induction was inhibited by the antioxidant 
PDTC and a similar effect was observed for the NF-IcB-in- 
duced Ir, B-ct gene [20]. 
The AP-1 family of transcription factors, which has been 
shown to be important for PMA and EGF induction of uPA 
mRNA in other types of cells [5,6,8] does not appear to be 
involved in uPA mRNA induction in the A549 cell line. In 
fact, while c-Jun mRNA was present in treated cells, no c-Fos 
mRNA could be detected. AP-1 binding activity, possibly due 
to other members of the Jun, ATF and Fos families, was 
present in untreated cells and was only weakly induced by 
PMA and TNF-cc Finally, while pretreatment with the anti- 
PDTC - + + _ + + _ + + _ 
PMA - - + + + - - _ 
TNF-¢c  . . . .  + + + + 
comp.  - . . . . .  + 
I 2 3 4 5 6 7 8 9 18  
NF-kB  
,e l - - -  Ap .  1 
Fig. 4. PDTC blocks activation of NF-~B DNA binding activity by 
PMA and TNF-cc Nuclear extracts of A549 cells treated with TNF- 
ct or PMA in conjunction with the antioxidant pyrrolidinedietilcar- 
bamate (PDTC), were used for EMSA with the ~¢B probe (Fig. 4). 
PDTC treatment alone (lanes 2 and 3, 100 and 150 laM). PMA and 
TNF-ct-treated ceils (lanes 4 and 7, respectively), PMA and TNF-ct 
co-treatment with 100 and 150 IxM PDTC (lanes 5, 6, 8 and 9). 
Lane 10; competition with a 60-fold excess of specific oligonucleo- 
tide. The same xtracts were tested for AP-1 binding activity. 
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Fig. 5. PDTC inhibits PMA and TNF-ct induction of uPA and IlcB- 
¢t mRNAs. A: Northern blots. B: Quantitation by comparison to 
GAPDH mRNA levels and densitometric s anning. Concentration 
used: PMA, 100 ng/ml nM; TNF-~t, 100 U/ml; PDTC, 150 p.M. 
oxidant PDTC slightly stimulated AP-1 binding activity, it 
had an inhibitory effect on uPA mRNA induction by PMA 
and TNF-cc Overall, our data lead to the conclusion that the 
NF-lcB transcription factor is involved in the activation of 
uPA gene transcription by PMA and TNF-ct in human 
A549 cells. This result is in agreement with the block of 
uPA gene expression by a RelA antisense oligonucleotide in 
a human ovarian carcinoma cell line [24]. 
In the 5' flanking region of the human uPA gene, 1¢B sites 
are present in at least two positions: immediately downstream 
of the enhancer (at -1865) and at -1590 [4,7,25]. The site at 
-1590 has an unusual 1¢B sequence, but has been shown to 
mediate PMA induction of uPA gene transcription and to 
bind both the RelA-NF-~cB1 and the RelA/c-Rel heterodi- 
mers [7]. The site at -1865 is highly homologous to the Ig1¢ 
and HIV classical sites, but its activity on uPA gene transcrip- 
tion has not been rigorously tested. In fact, in human HeLa, 
HepG2 and HT1080 cells, the deletion of this site did not 
prevent PMA induction [6,26]. However, in these cells the 
AP-1 sites appear particularly important in inducing uPA 
gene transcription [8,26]. 
Taken together these data suggest that the same transcrip- 
tion factor can play different roles in different cell lines pro- 
viding a mechanism to control gene expression i  a cell-spe- 
cific manner. 
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